Target Name: ANKS1B
NCBI ID: G56899
Review Report on ANKS1B Target / Biomarker Content of Review Report on ANKS1B Target / Biomarker
ANKS1B
Other Name(s): cajalin-2 | ANKS2 | E2A-PBX1-associated protein | ANKS1B variant 4 | Ankyrin repeat and sterile alpha motif domain-containing protein 1B (isoform a) | Amyloid-beta protein intracellular domain-associated protein 1 | EB1 | Ankyrin repeat and sterile alpha motif domain-containing protein 1B | ANS1B_HUMAN | Ankyrin repeat and sterile alpha motif domain-containing protein 1B (isoform d) | AIDA | cajalin 2 | Ankyrin repeat and sterile alpha motif domain containing 1B, transcript variant 1 | Ankyrin repeat and sterile alpha motif domain containing 1B, transcript variant 4 | Amyloid-beta precursor protein intracellular domain associated protein 1 | amyloid-beta precursor protein intracellular domain associated protein 1 | E2a-Pbx1-associated protein | ankyrin repeat and sterile alpha motif domain containing 1B | Ankyrin repeat and SAM domain-containing protein 1B | AIDA-1b | AIDA-1 | Cajalin-2 | EB-1 | Cajalin 2 | ANKS1B variant 1 | MGC26087

ANKS1B: A Protein Target for Various Diseases

ANKS1B (cajalin-2) is a protein that is expressed in various tissues throughout the body, including the brain, heart, and kidneys. It is a key regulator of the blood-brain barrier, which is responsible for controlling the movement of substances into and out of the brain. The blood-brain barrier is an essential barrier that helps to protect the brain from harmful substances, but it also makes it difficult for important drugs to reach the brain and treat diseases such as Alzheimer's and Parkinson's.

ANKS1B is also a potential drug target for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Studies have shown that ANKS1B is involved in many different cellular processes in the brain, including the regulation of ion channels, neurotransmitter release, and cell signaling. This makes it an attractive target for drugs that want to treat these diseases.

One of the main advantages of ANKS1B as a drug target is its central role in the regulation of the blood-brain barrier. The blood-brain barrier is a specialized barrier that separates the brain from the rest of the body, and it is designed to protect the brain from harmful substances. However, this barrier can also make it difficult for important drugs to reach the brain and treat diseases such as Alzheimer's and Parkinson's. By targeting ANKS1B, drugs can bypass the blood-brain barrier and directly target the brain cells that are affected by the disease.

ANKS1B is also involved in many different cellular processes in the brain, including the regulation of ion channels, neurotransmitter release, and cell signaling. This makes it an attractive target for drugs that want to treat neurodegenerative diseases such as Alzheimer's and Parkinson's. These diseases are characterized by the progressive loss of brain cells, and there is currently no cure. However, by targeting ANKS1B, drugs can potentially slow the progression of the disease and improve quality of life for patients.

ANKS1B is also a potential target for cancer, as it has been shown to be involved in the regulation of cell signaling processes in many different types of cancer. Studies have shown that ANKS1B is often overexpressed in cancer cells, and that inhibiting its activity can potentially be a effective treatment for cancer. Additionally, ANKS1B has also been shown to be involved in the regulation of cell signaling processes in neurodevelopmental disorders such as autism, which may also be a potential target for future drugs.

In conclusion, ANKS1B is a protein that is expressed in various tissues throughout the body, including the brain, heart, and kidneys. It is a key regulator of the blood-brain barrier and has been shown to be involved in many different cellular processes in the brain. As a result, ANKS1B is an attractive target for drugs that want to treat a wide range of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Protein Name: Ankyrin Repeat And Sterile Alpha Motif Domain Containing 1B

Functions: Isoform 2 may participate in the regulation of nucleoplasmic coilin protein interactions in neuronal and transformed cells

The "ANKS1B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ANKS1B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

ANKS3 | ANKS4B | ANKS6 | ANKUB1 | ANKZF1 | ANLN | Annexin | ANO1 | ANO10 | ANO2 | ANO3 | ANO4 | ANO5 | ANO6 | ANO7 | ANO7L1 | ANO8 | ANO9 | Anoctamin | ANOS1 | ANOS2P | ANP32A | ANP32A-IT1 | ANP32AP1 | ANP32B | ANP32C | ANP32D | ANP32E | ANPEP | ANTKMT | ANTXR1 | ANTXR2 | ANTXRL | ANTXRLP1 | ANXA1 | ANXA10 | ANXA11 | ANXA13 | ANXA2 | ANXA2P1 | ANXA2P2 | ANXA2P3 | ANXA2R | ANXA2R-AS1 | ANXA2R-OT1 | ANXA3 | ANXA4 | ANXA5 | ANXA6 | ANXA7 | ANXA8 | ANXA8L1 | ANXA8L2 | ANXA9 | AOAH | AOC1 | AOC2 | AOC3 | AOC4P | AOPEP | AOX1 | AOX2P | AP-1 Transcription Factor Complex | AP1AR | AP1B1 | AP1B1P1 | AP1G1 | AP1G2 | AP1M1 | AP1M2 | AP1S1 | AP1S2 | AP1S3 | AP2A1 | AP2A2 | AP2B1 | AP2M1 | AP2S1 | AP3B1 | AP3B2 | AP3D1 | AP3M1 | AP3M2 | AP3S1 | AP3S2 | AP4B1 | AP4B1-AS1 | AP4E1 | AP4M1 | AP4S1 | AP5B1 | AP5M1 | AP5S1 | AP5Z1 | APAF1 | APBA1 | APBA2 | APBA3 | APBB1 | APBB1IP